Literature DB >> 15513979

The ovarian markers of the FSH insufficiency in functional hypothalamic amenorrhoea.

S Jonard1, P Pigny, L Jacquesson, C Demerle-Roux, Y Robert, D Dewailly.   

Abstract

BACKGROUND: The purpose of this work was to revisit the gonadotrophin insufficiency of functional hypothalamic amenorrhoea (FHA) with the use of relevant ovarian markers.
METHODS: Serum anti-Mullerian hormone (AMH), estradiol (E2), inhibin B, LH and FSH were immunoassayed in 31 women with FHA and in 30 healthy women in early follicular phase. The ovarian antral follicle number (FN) was determined within two distinct diameter ranges (2-5 and 6-9 mm) by ultrasound in real time, the same day as the blood sampling.
RESULTS: The 2-5 mm FN was similar between the two groups, while the 6-9 mm FN was significantly less in FHA than in controls, in relation with lower serum FSH levels (r=0.428; P<0.024). Nine (29%) FHA patients had a low serum basal FSH level (i.e. <4.5 IU/l, 5th percentile of control values). In the 22 (71%) patients with apparently normal FSH, the mean 6-9 mm FN was similar to controls. However, in this sub-group, the mean AMH serum level and the AMH:2-5 mm FN ratio were significantly higher and the mean inhibin B serum level was significantly lower than in controls. No significant relationship was found between the serum LH levels and the FN, AMH or inhibin B values.
CONCLUSION: Only a minority of patients with FHA have a low serum basal FSH level, and we show that this is associated with fewer 6-9 mm follicles at the ovarian level. Despite a normal serum FSH level and 6-9 mm FN in the majority of patients with FHA, the functional follicle markers are abnormal. This suggests that the FSH action on the ovary is incomplete and is not properly reflected by its serum level nor by FN at ultrasound.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15513979     DOI: 10.1093/humrep/deh560

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  7 in total

1.  Clinical pregnancy in a woman with idiopathic hypogonadotropic hypogonadism and low AMH: utility of ovarian reserve markers in IHH.

Authors:  Crystal Chan; Kimberly Liu
Journal:  J Assist Reprod Genet       Date:  2014-08-12       Impact factor: 3.412

2.  Polycystic Ovary Syndrome Phenotype D Versus Functional Hypothalamic Amenorrhea With Polycystic Ovarian Morphology: A Retrospective Study About a Frequent Differential Diagnosis.

Authors:  Klara Beitl; Didier Dewailly; Rudolf Seemann; Marlene Hager; Jakob Bünker; Daniel Mayrhofer; Iris Holzer; Johannes Ott
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-02       Impact factor: 6.055

Review 3.  Exercise, Training, and the Hypothalamic-Pituitary-Gonadal Axis in Men and Women.

Authors:  Natalia Cano Sokoloff; Madhusmita Misra; Kathryn E Ackerman
Journal:  Front Horm Res       Date:  2016-06-27       Impact factor: 2.606

4.  Neuro-pharmacological reinstatement of ovulation and associated neurobiology in a macaque model of functional hypothalamic amenorrhoea.

Authors:  Cynthia L Bethea; Judy L Cameron
Journal:  Hum Reprod       Date:  2021-01-01       Impact factor: 6.918

Review 5.  Use of AMH in the Differential Diagnosis of Anovulatory Disorders Including PCOS.

Authors:  Martina Capuzzo; Antonio La Marca
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-03       Impact factor: 5.555

6.  The Reproductive Outcome of Women with Hypogonadotropic Hypogonadism in IVF.

Authors:  Chun-Mei Zhang; Hua Zhang; Rui Yang; Li-Xue Chen; Ping Liu; Rong Li; Jie Qiao; Ying Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-06       Impact factor: 6.055

7.  Basal and dynamic relationships between serum anti-Müllerian hormone and gonadotropins in patients with functional hypothalamic amenorrhea, with or without polycystic ovarian morphology.

Authors:  Marlene Hager; Johannes Ott; Julian Marschalek; Marie-Louise Marschalek; Clemens Kinsky; Rodrig Marculescu; Didier Dewailly
Journal:  Reprod Biol Endocrinol       Date:  2022-07-04       Impact factor: 4.982

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.